14,726 results match your criteria Juvenile Rheumatoid Arthritis


COVID-19 in a child with Still's disease (systemic juvenile idiopathic arthritis): 9th case described.

Eur Rev Med Pharmacol Sci 2021 Jul;25(13):4443-4444

Institute for Health Sciences from Federal University of Bahia, Salvador, Bahia, Brazil.

View Article and Full-Text PDF

Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for Severe COVID-19.

Authors:
Dinah V Parums

Med Sci Monit 2021 Jul 19;27:e933973. Epub 2021 Jul 19.

Science Editor, Medical Science Monitor, International Scientific Information, Inc., Mellville, NY, USA.

Vaccinated, non-vaccinated, and immunosuppressed individuals will continue to be infected with SARS-CoV-2. Therefore, there is a priority to develop treatments that reduce the severity of COVID-19 in patients who require hospital admission. Interleukin-6 (IL-6) is a proinflammatory cytokine. Read More

View Article and Full-Text PDF

Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study.

Rheumatol Ther 2021 Jul 18. Epub 2021 Jul 18.

Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Room 3C56, Health Research Innovation Centre, 3280 Hospital Drive NW, Calgary, AB, T2N 4Z6, Canada.

Introduction: Juvenile idiopathic arthritis (JIA) is a chronic rheumatic disease, whose multifaceted care path can lead to significant expenditure for the healthcare system. We aim to assess the real-world healthcare resource use (HCRU) and associated cost for children with JIA in a single center in Canada.

Methods: A single-center consecutive cohort of newly diagnosed patients with JIA attending the pediatric rheumatology clinic from 2011 to 2019 was identified using an administrative data algorithm and electronic medical charts. Read More

View Article and Full-Text PDF

Diffuse alveolar hemorrhage in children with trisomy 21.

Pediatr Rheumatol Online J 2021 Jul 17;19(1):114. Epub 2021 Jul 17.

Department of Pediatrics, Section of Pediatric Rheumatology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

Background: Respiratory conditions are the leading cause of hospitalization and death in children with Trisomy 21 (T21). Diffuse alveolar hemorrhage (DAH) occurs at higher frequency in children with T21; yet, it is not widely studied nor is there a standardized approach to diagnosis or management. The objective of this study was to identify children with T21 and DAH in order to understand contributing factors and identify opportunities to improve outcomes. Read More

View Article and Full-Text PDF

OBSIDIAn - real world evidence of Originator to BioSImilar Drug switch in juvenile idiopathic arthritis.

Rheumatology (Oxford) 2021 Jul 17. Epub 2021 Jul 17.

Rheumatology Unit, Meyer Children's University Hospital; Florence, Italy.

Objectives: Limited data about use of biosimilars are available in children with Juvenile Idiopathic Arthritis (JIA). This study therefore aimed to evaluate long-term efficacy and safety of switching from etanercept (ETA) and adalimumab (ADA) originators to their biosimilars, in children with JIA, in a real-world setting.

Methods: This is a retro-prospective non-interventional multicentre Italian comparative cohort study. Read More

View Article and Full-Text PDF

Targeting immune checkpoints in juvenile idiopathic arthritis: accumulating evidence.

Pediatr Res 2021 Jul 16. Epub 2021 Jul 16.

Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

View Article and Full-Text PDF

Seventeen years of misdiagnosis in rare dyslipidaemia: a case report of sitosterolaemia in a young female.

Eur Heart J Case Rep 2021 May 19;5(5):ytab188. Epub 2021 May 19.

Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus, Denmark.

Background : Sitosterolaemia is a rare, autosomal recessive dyslipidaemia with increased absorption of dietary plant sterol and often presents with hypercholesterolaemia, xanthomas, and haematologic manifestations. If left untreated, sitosterolaemia can lead to high symptomatic burden and coronary artery disease (CAD).

Case Summary : We describe a case of a young female who initially presented at 4 years of age with classic manifestations of sitosterolaemia. Read More

View Article and Full-Text PDF

Long Term Experience in Patients With JIA-Associated Uveitis in a Large Referral Center.

Front Pediatr 2021 28;9:682327. Epub 2021 Jun 28.

Department of Ophthalmology, San Raffaele Scientific Institute, University Vita-Salute, Milan, Italy.

To describe demographic, clinical and therapeutic findings of a large cohort of patients with JIA-associated uveitis in a nationwide referral pediatric rheumatology and uveitis center in Northern Italy. Retrospective study of 125 patients with JIA-associated uveitis followed from 2009 to 2019. Demographic and rheumatologic features including JIA ILAR classification, age at onset, and laboratory data were recorded. Read More

View Article and Full-Text PDF

The Use of Extracorporeal Life Support in Children With Immune-Mediated Diseases.

Pediatr Crit Care Med 2021 Jul 14. Epub 2021 Jul 14.

Department of Pediatrics, Division of Critical Care Medicine, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA. Department of Pediatrics, Oregon Health and Sciences University, Portland, OR. Department of Cardiology, Children's Hospital, Boston, Department of Pediatrics, Harvard Medical School, Boston, MA. Department of Pediatrics, Division of Rheumatology, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA. University of Washington, Seattle, WA.

Objectives: To describe the use and outcomes of extracorporeal membrane oxygenation support among children with immune-mediated conditions.

Design: Retrospective cohort study.

Setting: The Extracorporeal Life Support Organization registry. Read More

View Article and Full-Text PDF

The immunoregulatory function of peripheral blood CD71 erythroid cells in systemic-onset juvenile idiopathic arthritis.

Sci Rep 2021 Jul 13;11(1):14396. Epub 2021 Jul 13.

Departments of Pediatrics, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.

CD71 erythroid cells (CECs) are recognized to have an immunoregulatory function via direct cell-cell interaction and soluble mediators. Circulating CECs appear in newborns or patients with hemolytic and cardiopulmonary disorders. To assess the biological role of CECs in systemic inflammation, we studied the gene expression and function in systemic-onset juvenile idiopathic arthritis (SoJIA). Read More

View Article and Full-Text PDF

Advances in Juvenile Spondyloarthritis.

Curr Rheumatol Rep 2021 Jul 13;23(9):70. Epub 2021 Jul 13.

Division of Rheumatology, Children's National Hospital and National Institute of Arthritis and Musculoskeletal and Skin Diseases, Building 10 10N-311, 9000 Rockville Pike, Bethesda, MD, 20892, USA.

Purpose: To provide an overview of recent studies on pathogenesis, diagnosis, and management of juvenile spondyloarthritis (JSpA).

Recent Findings: Recent studies show differences in gut microbiome in patients with JSpA in comparison to healthy controls. There is increased recognition of the impact of the innate immune system on disease pathology. Read More

View Article and Full-Text PDF

Next-Generation HLA Sequence Analysis Uncovers Shared Risk Alleles Between Clinically Distinct Forms of Childhood Uveitis.

Invest Ophthalmol Vis Sci 2021 Jul;62(9):19

Department of Ophthalmology, University Medical Center Utrecht, Utrecht University, The Netherlands.

Purpose: Classical alleles of the human leukocyte antigen (HLA) complex have been linked to specific entities of pediatric noninfectious uveitis, yet genetic predisposition encoded by the HLA super-locus across the patient population remains understudied.

Methods: We performed next-generation full-length sequencing of HLA-A, HLA-B, HLA-C, HLA-DPB1, HLA-DQB1, and HLA-DRB1 in 280 cases. Dense genotype data from 499 Dutch controls from Genome of the Netherlands were imputed using an HLA-specific reference panel (n = 5225 samples from European ancestry). Read More

View Article and Full-Text PDF

A case report of intracranial hypertension and aseptic meningitis: anti-tumor necrosis factor associated or juvenile idiopathic arthritis related.

Turk J Pediatr 2021 ;63(3):522-526

Division of Pediatric Rheumatology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Background: The adverse effects of tumor necrosis factor alpha inhibitors (TNFi) are well characterized but rare adverse events are increasing day by day.

Case: We presented an 18-year-old girl with rheumatoid factor positive polyarticular juvenile idiopathic arthritis (JIA) who developed fever, headache, and nausea after the second dose of adalimumab. In addition to her suspicious complaints for meningitis, she had bilateral papilledema and partial abducens nerve palsy. Read More

View Article and Full-Text PDF
January 2021

Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms.

Exp Mol Med 2021 Jul 12. Epub 2021 Jul 12.

Laborabory of Immune Regulation, Immunology Frontier Research Center, Osaka University, 3-1 Yamadaoka, Suita, Osaka, Japan.

Interleukin-6 (IL-6) plays a crucial role in host defense against infection and tissue injuries and is a bioindicator of multiple distinct types of cytokine storms. In this review, we present the current understanding of the diverse roles of IL-6, its receptors, and its signaling during acute severe systemic inflammation. IL-6 directly affects vascular endothelial cells, which produce several types of cytokines and chemokines and activate the coagulation cascade. Read More

View Article and Full-Text PDF

A Novel Pathogenic Variant in a Mother and Daughter with Blau Syndrome.

Ophthalmic Genet 2021 Jul 12:1-12. Epub 2021 Jul 12.

Uveitis and Scleritis Service, Moorfields Eye Hospital NHS Foundation Trust, London, UK.

Background: Blau syndrome (BS) is a rare dominantly-inherited autoinflammatory disorder characterized by the triad of arthritis, uveitis and dermatitis that is consequence of gain-of-function mutations. We describe the clinical features and genetic basis of a family with two affected members in consecutive generations affected with childhood onset arthritis and uveitis.

Materials And Methods: Clinical features were retrospectively collected from clinical records. Read More

View Article and Full-Text PDF

Association between high mobility group box 1 protein and juvenile idiopathic arthritis: a prospective longitudinal study.

Pediatr Rheumatol Online J 2021 Jul 12;19(1):112. Epub 2021 Jul 12.

Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, 136, Zhongshan 2nd Road, Yuzhong District, Chongqing, 400014, People's Republic of China.

Objective: To analyze the levels of high mobility group box 1 (HMGB1) protein on different courses of juvenile idiopathic arthritis (JIA).

Methods: In our prospective longitudinal study, children with JIA were included with their blood samples collected at the first visit, 1-month, 3-month, and 6-month follow-up, respectively. Samples were also collected from healthy controls and children with reactive arthritis at the first visit. Read More

View Article and Full-Text PDF

Juvenile Idiopathic Arthritis, Marriage and Parenthood: A Nationwide Matched Cohort Study.

Rheumatology (Oxford) 2021 Jul 10. Epub 2021 Jul 10.

Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.

Objectives: To compare trajectories of marriage and parenthood in individuals with juvenile idiopathic arthritis (JIA) vs the general population.

Methods: Patients with JIA (n = 4399) were identified in the Swedish National.

Patient: Register (2001-2016) and individually matched to up to five general population comparators on birthyear, sex, and residence county (n = 21 981). Read More

View Article and Full-Text PDF

Updates in Juvenile Idiopathic Arthritis.

Adv Pediatr 2021 Aug;68:143-170

Division of Allergy/Immunology/Rheumatology, David Geffen School of Medicine, UCLA, Mattel Children's Hospital, 10833 Le Conte Avenue, MDCC 12-430, Los Angeles, CA 90095, USA; Pediatric Rheumatology, Cottage Children's Medical Center, 400 West Pueblo Street, PO Box 689, Santa Barbara, CA 93110-0689, USA. Electronic address:

View Article and Full-Text PDF

Reducing fatigue in pediatric rheumatic conditions: a systematic review.

Pediatr Rheumatol Online J 2021 Jul 8;19(1):111. Epub 2021 Jul 8.

Department of Pediatrics, Wilhelmina Children's Hospital, Center for Child Development Exercise and Physical Literacy, University Medical Center Utrecht, Utrecht University, Suite KB.02.055.1, Internal mail KB.02.056.0, PO Box 85090, 3508, AB, Utrecht, The Netherlands.

Background: Although fatigue is a prevalent distressing symptom in children and adolescents with Pediatric Rheumatic Conditions (PRCs), intervention studies designed for reducing fatigue in PRCs are limited.

Aim: To systematically review evidence regarding the efficacy of interventions intended to reduce fatigue in patients with PRCs.

Methods: Comprehensive electronic searches were performed in PubMed/ MEDLINE, Embase, Web of Science and Cinahl. Read More

View Article and Full-Text PDF

An ultrasound protocol for temporomandibular joint in juvenile idiopathic arthritis: a pilot study.

Dentomaxillofac Radiol 2021 Jul 8:20200399. Epub 2021 Jul 8.

Orthodontics, Dental School, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.

Objectives: As it is well known, the diagnosis of temporomandibular joint (TMJ) involvement in patients affected by Juvenile Idiopathic Arthritis (JIA) is important to avoid the impairment of mandibular growth. In this context, Magnetic Resonance Imaging (MRI) is the gold-standard for detection of TMJ involvement, however it is expensive and requires patients' collaboration. The aim of this study was to evaluate if ultrasound may be used as an alternative tool to investigate the acute signs of TMJ involvement in JIA patients. Read More

View Article and Full-Text PDF

[Quality of life and disease activity assessment in juvenile idiopathic arthritis].

Rev Med Inst Mex Seguro Soc 2021 Jun 14;59(2):133-140. Epub 2021 Jun 14.

Instituto Mexicano del Seguro Social, Centro Médico Nacional "Manuel Ávila Camacho", Hospital de Especialidades, Dirección General. Puebla, Puebla, México.

Background: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatological disease in children. It is a multisystemic, dynamic pathophysiology of unknown cause and genetically heterogeneous.

Objective: To compare the quality of life and illness' activity in patients with juvenile idiopathic arthritis, from urban, suburban and rural areas. Read More

View Article and Full-Text PDF

Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy.

Authors:
Hanna Kim

Curr Opin Rheumatol 2021 Jul 6. Epub 2021 Jul 6.

Juvenile Myositis Pathogenesis and Therapeutics Unit, National Institute of Arthritis Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland, USA.

Purpose Of Review: This review provides updates regarding the role of interferon (IFN) in juvenile dermatomyositis (JDM), including comparison to interferonopathies and therapeutic implications.

Recent Findings: Transcriptomic and protein-based studies in different tissues and peripheral IFN-α assessment have demonstrated the importance of the dysregulated IFN pathway in JDM. Additional studies have validated IFN-regulated gene and protein expression correlation with disease activity in blood and muscle, with potential to predict flares. Read More

View Article and Full-Text PDF

Duration of inactive disease while off disease-modifying anti-rheumatic drugs seems to influence flare rates in juvenile idiopathic arthritis: an observational retrospective study.

Acta Reumatol Port 2021 Apr-Jun;46(2):120-125

Universidade Federal de São Paulo - UNIFESP.

Background: many Juvenile Idiopathic Arthritis (JIA) patients reach inactivity while medicated, but there are no guidelines to determine the moment or method for discontinuing medications. We present the flare rates and remission and possible influencing factors after therapy discontinuation in children with JIA.

Methods: data was collected from charts of JIA patients (n=70) in remission on medication, who had their drugs withdrawn. Read More

View Article and Full-Text PDF

Nothing about us without us: involving patient collaborators for machine learning applications in rheumatology.

Ann Rheum Dis 2021 Jul 5. Epub 2021 Jul 5.

Centre for Health Informatics, The University of Manchester, Manchester, UK.

Novel machine learning methods open the door to advances in rheumatology through application to complex, high-dimensional data, otherwise difficult to analyse. Results from such efforts could provide better classification of disease, decision support for therapy selection, and automated interpretation of clinical images. Nevertheless, such data-driven approaches could potentially model noise, or miss true clinical phenomena. Read More

View Article and Full-Text PDF

Effect of first-line biologic initiation on glucocorticoid exposure in children hospitalized with new-onset systemic juvenile idiopathic arthritis: emulation of a pragmatic trial using observational data.

Pediatr Rheumatol Online J 2021 Jul 5;19(1):109. Epub 2021 Jul 5.

Children's Hospital of Philadelphia, Division of Rheumatology, Philadelphia, PA, USA.

Background: Glucocorticoid exposure is a significant driver of morbidity in children with systemic juvenile idiopathic arthritis (sJIA). We determined the effect of early initiation of biologic therapy (IL-1 or IL-6 inhibition) on glucocorticoid exposure in hospitalized patients with new-onset sJIA.

Methods: We emulated a pragmatic sequence of trials ("pseudo-trials") of biologic initiation in children (≤ 18 years) hospitalized with new-onset sJIA utilizing retrospective data from an administrative database from 52 tertiary care children's hospitals from 2008 to 2019. Read More

View Article and Full-Text PDF

The vaccine coverage and vaccine immunity status and risk factors of non-protective levels of antibodies against vaccines in children with juvenile idiopathic arthritis: cross-sectional Russian tertiary Centre study.

Pediatr Rheumatol Online J 2021 Jul 5;19(1):108. Epub 2021 Jul 5.

Pediatric Research and Clinical Center for Infection Diseases, Saint-Petersburg, Russia.

Background: Immunosuppressive drugs, incomplete vaccine coverage, immune system dysregulation might be factors of a low level of anti-vaccine antibodies in JIA patients. The study aimed to evaluate vaccine coverage, post-vaccine immunity, and risk factors of non-protective levels of antibodies against measles, mumps, rubella, hepatitis B, and diphtheria in JIA patients.

Methods: A cross-sectional study included 170 children diagnosed with JIA aged 2 to 17 years who received routine vaccinations against measles, rubella, mumps (MMR), diphtheria, and hepatitis B national vaccine schedule. Read More

View Article and Full-Text PDF

New developments implicating IL-21 in autoimmune disease.

J Autoimmun 2021 Aug 2;122:102689. Epub 2021 Jul 2.

Devision of Rheumatology, Department of Medicine, Penn State MS Hershey Medical Center, Hershey, PA, 17033, USA.

Elevated interleukin (IL)-21 is a common finding in the tissues and/or sera of patients with autoimmune disease. CD4 T cells are the primary producers of IL-21; often the IL-21 producing CD4 T cells will express molecules associated with follicular helper cells (T). Recent work has shown that the CD4 T cell-derived IL-21 is able to promote effector functions and memory differentiation of CD8 T cells in chronic infections and cancer. Read More

View Article and Full-Text PDF

Pneumococcal vaccine in patients with idiopathic juvenile arthritis in treatment with tumor necrosis factor inhibitors.

Allergol Immunopathol (Madr) 2021 1;49(4):149-154. Epub 2021 Jul 1.

Department of Paediatrics, School of Medicine, University of Chile, Santiago de Chile, Chile.

Introduction: Juvenile idiopathic arthritis (JIA) is the most common rheumatological disease of childhood. The therapy with tumor necrosis factor (TNF) inhibitors (TNFi) in JIA patients has demonstrated efficacy and safety. The most reported adverse event is the high susceptibility to infections. Read More

View Article and Full-Text PDF

Juvenile Idiopathic Arthritis With Epstein-Barr Virus-Associated Smooth Muscle Tumor in a 6-Year-Old Girl: A Rare Case Report.

Front Pediatr 2021 18;9:680113. Epub 2021 Jun 18.

Department of Nephrology and Rheumatology of Hunan Children's Hospital, Changsha, China.

Herein, we reported a rare case of Epstein-Barr virus-associated smooth muscle tumor (EBV-SMT) combined with juvenile idiopathic arthritis (JIA) in a 6-year old girl without HIV, organ transplantation, or congenital immunodeficiency. The patient suffered from pain in the bilateral hip joints, which drastically affected her physical activity. Consequently, she was diagnosed with JIA (September 2019). Read More

View Article and Full-Text PDF